Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Aclaris Therapeutics (ACRS) EBT Margin (2017 - 2025)

Aclaris Therapeutics has reported EBT Margin over the past 9 years, most recently at 1629.34% for Q4 2025.

  • Quarterly results put EBT Margin at 1629.34% for Q4 2025, down 57004.0% from a year ago — trailing twelve months through Dec 2025 was 878.33% (down 16267.0% YoY), and the annual figure for FY2025 was 878.33%, down 17285.0%.
  • EBT Margin for Q4 2025 was 1629.34% at Aclaris Therapeutics, down from 464.69% in the prior quarter.
  • Over the last five years, EBT Margin for ACRS hit a ceiling of 10.57% in Q4 2023 and a floor of 1702.25% in Q2 2023.
  • Median EBT Margin over the past 5 years was 1023.23% (2021), compared with a mean of 909.06%.
  • Peak annual rise in EBT Margin hit 130507bps in 2024, while the deepest fall reached -104872bps in 2024.
  • Aclaris Therapeutics' EBT Margin stood at 1525.18% in 2021, then soared by 75bps to 375.07% in 2022, then skyrocketed by 97bps to 10.57% in 2023, then crashed by -9917bps to 1059.3% in 2024, then crashed by -54bps to 1629.34% in 2025.
  • The last three reported values for EBT Margin were 1629.34% (Q4 2025), 464.69% (Q3 2025), and 922.34% (Q2 2025) per Business Quant data.